SCHEMBL206949

SCHEMBL206949

COc1ccc2[nH]cc(CCNC(=O)CCC(=O)NC3CCC(Cc4ccccc4)(N4CCOCC4)CC3)c2c1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.54
BCHE P06276 4/20 0.54
ACHE P22303 4/20 0.54
MTNR1A P48039 4/20 0.52
MTNR1B P49286 4/20 0.52
ALDH1A1 P00352 1/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
FAAH O00519 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207365 0.86 SIGMAR1 (0.47) SIGMAR1ALDH1A1MAPTLMNAMEN1
SCHEMBL207774 0.83 BCHE (0.42) BCHEACHEALDH1A1MAPTKDM4E
SCHEMBL206838 0.82 SIGMAR1 (0.47) SIGMAR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL5155120 0.81 ACHE (0.41) SIGMAR1BCHEACHEMTNR1AMTNR1B
SCHEMBL207061 0.79 ALPL (0.41) SIGMAR1ALDH1A1MAPTMEN1KMT2A
SCHEMBL206236 0.79 KDM4E (0.47) ALDH1A1MAPTKDM4ELMNAMEN1
SCHEMBL208507 0.79 ACHE (0.59) SIGMAR1BCHEACHEMTNR1AMTNR1B
SCHEMBL207752 0.77 HSD17B10 (0.50) MEN1KMT2A
SCHEMBL9192798 0.75 MTNR1A (0.68) BCHEACHEMTNR1AMTNR1BALDH1A1
SCHEMBL7501961 0.73 KMT2A (0.81) ACHEMTNR1AMTNR1BALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD SIGMAR1 3262/4885BCHE 894/4885ACHE 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.